Endometrial carcinoma can develop in patients on tamoxifen therapy.

Breast cancer constitutes 54.8 percent of deaths from malignancies in female genital tract in Malaysia, 19951• It is also the second most common death (19.4%) from malignancies in females in Malaysia. The use of adjuvant tamoxifen therapy continuously for five or more years has contributed to longer survivals in these patients. Several recent reports of possible association between tamoxifen treatment and endometrial pathologies, such as endometrial hyperplasia, endometrial polyps, adenomyosis, endometrial carcinoma and endometrial sarcoma are of concern to the clinicians. We present here 2 cases of advanced endometrial carcinoma after tamoxifen therapy.